Psoriatic Arthritis: Analysis of key brands.
By Christina Vasiliou, Senior Analyst
22 July 2014
I joined Datamonitor Healthcare in early 2014, having completed an MPhil in Bioscience Enterprise at the University of C...
Read full bio
Although the anti-tumor necrosis factor (TNF) biologics have revolutionized the treatment of psoriatic arthritis (PsA), key opinion leaders note that a significant proportion of patients are inadequate responders to anti-TNF therapy and that there is an unmet need for safe and efficacious therapies with novel mechanisms of action. Stelara and Otezla, two novel therapies, entered the PsA market in 2013 and 2014, respectively, opening the door for other non-anti-TNF drugs that are currently in the PsA pipeline.
Datamonitor Healthcare has produced an in-depth analysis of key brands for PsA across the US, Japan, and five major EU markets, including a review of new clinical data and commercial drug attributes to determine competitiveness in the marketplace.
How will our psoriatic arthritis marketed drugs report benefit you?
- Gain competitive insight
Compare marketed and pipeline therapies against the gold-standard therapy in PsA, Humira, in Datamonitor Healthcare’s clinical and commercial assessment model, allowing you to benchmark your product against the current market leader.
- Identify market needs
Gain an understanding of the limitations of the marketed drugs and the existing unmet need in PsA, allowing you to identify the clinical improvements pipeline therapies will have to demonstrate in order to gain a foothold in the market.
- Explore investment opportunities
Gain insight into how the approvals of Stelara and Otezla in 2013 and 2014 respectively will open the door to more interleukin inhibitors and oral small molecules with novel mechanisms of action that are currently under development for PsA.
Key questions answered
- Why is Humira considered the gold-standard therapy in Datamonitor Healthcare’s clinical and commercial assessment model and how do the other marketed drugs compare to it?
- What limitations do key opinion leaders identify in the profiles of the marketed drugs?
- What factors influence physician prescribing decisions?
- In what lines of therapy and which patient populations are the marketed drugs currently used?
|Drug List:||Companies Mentioned:|